MDT

Medtronic PLC

Add to Watchlist

Advanced Chart

92.320

+0.31(0.337%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

92.500

Open

92.040

VWAP

92.21

Vol

6.68M

Mkt Cap

118.29B

Low

91.320

Amount

616.42M

EV/EBITDA(TTM)

14.32

Total Shares

1.28B

137.67B

EV/OCF(TTM)

19.54

P/S(TTM)

3.54

Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q3

FY2026Q2

FY2026Q1

8.76B

+5.65%

1.378

-0.83%

8.74B

+4%

1.324

+5.08%

8.37B

+5.76%

1.229

-0.09%

Estimates Revision

The market is revising Upward the revenue expectations for Medtronic plc (MDT) for FY2026, with the revenue forecasts being adjusted by 0.84% over the past three months. During the same period, the stock price has changed by 9.51%.

Revenue Estimates for FY2026

Revise Upward

+0.84%

In Past 3 Month

EPS Estimates for FY2026

Revise Downward

-4.83%

In Past 3 Month

Stock Price

Go Up

+9.51%

In Past 3 Month

23 Analyst Rating

4.30% Upside

Wall Street analysts forecast MDT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDT is 96.29 USD with a low forecast of 87.00 USD and a high forecast of 110.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

12 Buy

11 Hold

0 Sell

Moderate Buy

4.30% Upside

Current: 92.320

Low

87.00

Averages

96.29

High

110.00

4.30% Upside

Current: 92.320

Low

87.00

Averages

96.29

High

110.00

Mizuho

NULL -> Outperform

maintain

$98 -> $100

2025-07-16

Reason

Mizuho

Price Target

$98 -> $100

2025-07-16

maintain

NULL -> Outperform

Reason

Mizuho raised the firm's price target on Medtronic to $100 from $98 and keeps an Outperform rating on the shares. The firm adjusted price targets in medical devices and diagnostics ahead of the Q2 reports.

Morgan Stanley

Overweight

maintain

$98 -> $107

2025-07-15

Reason

Morgan Stanley

Price Target

$98 -> $107

2025-07-15

maintain

Overweight

Reason

Morgan Stanley raised the firm's price target on Medtronic to $107 from $98 and keeps an Overweight rating on the shares. The firm continues to like the MedTech industry setup into Q2 on relative stability in procedure volumes and hospital capital expenditures across the space, the analyst tells investors in a research note.

Stifel

Hold

maintain

$87

2025-07-11

Reason

Stifel

Price Target

$87

2025-07-11

maintain

Hold

Reason

Stifel maintains a Hold rating and $87 price target on Medtronic shares. The Centers for Medicare & Medicaid Services' initial proposal for renal denervation reimbursement "seems positive," with a final decision expected by October 8, the analyst tells investors in a research note.

JPMorgan

Neutral

maintain

2025-07-11

Reason

JPMorgan

Price Target

2025-07-11

maintain

Neutral

Reason

JPMorgan keeps a Neutral rating on Medtronic after the Centers for Medicare and Medicaid Services released a proposed national coverage decision for renal denervation. The decision calls for coverage for a broad swath of hypertensive patients, the analyst tells investors in a research note. JPMorgan says there is no arguing that a broad national coverage decision f for renal denervation is a win for Medtronic. This will allow the company to begin targeting this potentially multi-billion dollar opportunity once the final rule is released in October, contends the analyst. However, JPMorgan believes it will "take some time to get there" as the company will need to educate primary care physicians and general cardiologists.

BTIG

Ryan Zimmerman

Neutral

maintain

2025-07-11

Reason

BTIG

Ryan Zimmerman

Price Target

2025-07-11

maintain

Neutral

Reason

BTIG analyst Ryan Zimmerman keeps a Neutral rating on Medtronic after Centers for Medicare and Medicaid Services provided a proposed national coverage decision for renal denervation. As anticipated, CMS is proposing to cover renal denervation for uncontrolled hypertension, the analyst tells investors in a research note. BTIG says that while the news was expected, it is still a win for Medtronic. The company has been preparing sites for coverage with the launch of Symplicity Spyral, the firm points out. BTIG believes the decision opens up Medtronic to a "massive" potential patient pool.

Citi

Joanne Wuensch

Buy

maintain

$98 -> $99

2025-07-09

Reason

Citi

Joanne Wuensch

Price Target

$98 -> $99

2025-07-09

maintain

Buy

Reason

Citi analyst Joanne Wuensch raised the firm's price target on Medtronic to $99 from $98 and keeps a Buy rating on the shares. The firm adjusted targets in medical technology as part of a Q2 earnings preview.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Medtronic PLC (MDT.N) is 16.63, compared to its 5-year average forward P/E of 17.55. For a more detailed relative valuation and DCF analysis to assess Medtronic PLC 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

17.55

Current PE

16.63

Overvalued PE

20.42

Undervalued PE

14.69

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

14.79

Current EV/EBITDA

13.79

Overvalued EV/EBITDA

16.84

Undervalued EV/EBITDA

12.74

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

3.90

Current PS

3.34

Overvalued PS

4.66

Undervalued PS

3.15

Financials

Annual

Quarterly

FY2025Q4

YoY :

+3.94%

8.93B

Total Revenue

FY2025Q4

YoY :

-17.59%

1.92B

Operating Profit

FY2025Q4

YoY :

+61.40%

1.06B

Net Income after Tax

FY2025Q4

YoY :

+67.35%

0.82

EPS - Diluted

FY2025Q4

YoY :

-11.96%

2.07B

Free Cash Flow

FY2025Q4

YoY :

-3.61%

58.45

Gross Profit Margin - %

FY2025Q4

YoY :

-3.80%

15.46

FCF Margin - %

FY2025Q4

YoY :

+54.82%

11.89

Net Margin - %

FY2025Q4

YoY :

+24.01%

6.92

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

1.9M

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 167.88% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

1.3M

Volume

6-9

Months

1.2M

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

661.3K

Volume

Months

6-9

246.9K

Volume

Months

0-12

9.2K

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

40.5K

USD

3-6

Months

107.0K

USD

6-9

Months

16.0K

USD

0-12

Months

40.5K

USD

Bought

0-3

16.0K

USD

Months

3-6

24.0K

USD

Months

6-9

8.0K

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

1.9M

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

MDT News & Events

Events Timeline

2025-07-21 (ET)

2025-07-21

08:48:31

Medtronic secures CE Mark for MiniMed 780G System

2025-07-11 (ET)

2025-07-11

12:23:32

Video: Medtronic outperforms down market with CMS win

2025-07-11

09:55:01

Early notable gainers among liquid option names on July 11th

News

3.0

07-23NASDAQ.COM

Should You Buy or Sell Boston Scientific Stock Ahead of Its Upcoming Earnings?

7.0

07-21Benzinga

Court Nixes Jury Award Over Medtronic's Heart Valve Infringement Claim

9.0

07-21Newsfilter

Medtronic secures CE Mark for MiniMed™ 780G System for insulin-requiring people with diabetes including expanded indications in children as young as two, during pregnancy, and for type 2 diabetes